Zalicus
Zalicus discovers and develops novel-target pain therapies, including calcium channel modulator for chronic and acute inflammatory pain.
Launch date
Employees
Market cap
-
Enterprise valuation
€31—46m (Dealroom.co estimates Jun 2011.)
Cambridge Massachusetts (HQ)
Financials
Estimates*
| EUR | 2015 |
|---|---|
| R&D budget | 28.0m |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$32.0m | Series C | ||
$29.5m | Series D | ||
$15.0m | Series E | ||
| N/A | $8.5m | Early VC | |
N/A | Acquisition | ||
| Total Funding | €77.3m | ||
Recent News about Zalicus
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.